Evidence map›Paper›PMID 37592080›Full record

ArticleGene therapy2024

Safety and biodistribution of XC001 (encoberminogene rezmadenovec) gene therapy in rats: a potential therapy for cardiovascular diseases.

Duncan J Stewart, Albert Gianchetti, Dawn Byrnes, Howard C Dittrich, Barb Thorne, Linda L Manza, Rickey R Reinhardt

Abstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Duncan J StewartSinclair Centre for Regenerative Medicine, Ottawa Hospital Research Institute and the Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. djstewart@toh.ca.ORCID 0000-0002-9113-8691
Albert GianchettiXyloCor Therapeutics, Wayne, PA, USA.
Dawn ByrnesXyloCor Therapeutics, Wayne, PA, USA.
Howard C DittrichXyloCor Therapeutics, Wayne, PA, USA.
Barb ThorneXyloCor Therapeutics, Wayne, PA, USA.
Linda L ManzaPharmaron (San Diego) Lab Services LLC, San Diego, CA, USA.
Rickey R ReinhardtXyloCor Therapeutics, Wayne, PA, USA.
aTyr Pharma (United States) · USUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenovirus-mediated gene therapy holds promise for the treatment of cardiovascular diseases such as refractory angina. However, potential concerns around immunogenicity and vector dissemination from the target injected tissue require evaluation. This study was undertaken to evaluate the safety and biodistribution of XC001, a replication-deficient adenovirus serotype 5 vector expressing multiple isoforms of human vascular endothelial growth factor (VEGF), following direct administration into normal rat myocardium. Animals received the buffer formulation or increasing doses of XC001 (1 × 10

Indexed as

Cardiovascular DiseasesVascular Endothelial Growth Factor AAnimalsGenetic TherapyGenetic VectorsHumansRatsTissue DistributionVascular Endothelial Growth FactorsVascular Endothelial Growth Factor AVascular Endothelial Growth Factors

Identifiers

PMID37592080
OpenAlexW4385902677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.